Skip to main content
. 2017 Dec 21;23(47):8376–8386. doi: 10.3748/wjg.v23.i47.8376

Figure 1.

Figure 1

Relationship between the tumor-associated neutrophil-to-lymphocyte ratio and tumor recurrence. A: Representative immunohistochemical staining for CD15 (left) and CD8 (right); B: Significant differences in the TA-NLR were observed between the recurrence group (0.46% ± 0.05%, mean ± SE) and the non-recurrence group (0.24% ± 0.03%, P < 0.001). TA-NLR: Tumor-associated neutrophil-to-lymphocyte ratio.